Brain morphological changes in hypokinetic dysarthria of Parkinson's disease and use of machine learning to predict severity.

08:00 EDT 20th March 2020 | BioPortfolio

Summary of "Brain morphological changes in hypokinetic dysarthria of Parkinson's disease and use of machine learning to predict severity."

Up to 90% of patients with Parkinson's disease (PD) eventually develop the speech and voice disorder referred to as hypokinetic dysarthria (HD). However, the brain morphological changes associated with HD have not been investigated. Moreover, no reliable model for predicting the severity of HD based on neuroimaging has yet been developed.


Journal Details

This article was published in the following journal.

Name: CNS neuroscience & therapeutics
ISSN: 1755-5949


DeepDyve research library

PubMed Articles [24023 Associated PubMed Articles listed on BioPortfolio]

Early diagnosis of Parkinson's disease using machine learning algorithms.

Parkinson's disease is caused by the disruption of the brain cells that produce substance to allow brain cells to communicate with each other, called dopamine. The cells that produce dopamine in the b...

Quantitative Electroencephalography Characteristics for Parkinson's Disease: A Systematic Review.

Individualized treatment guided by biomarkers certainly will play a crucial role in the more effective treatment of various neurological diseases in the near future. Identifying the electroencephalogr...

Social cognition impairments in Parkinson's disease.

Parkinson's disease is the second most common neurodegenerative disease of the elderly caused by the neurodegenerative process in different parts of the brain, which resulted in motor and non-motor sy...

Investigation of the roles of dysbindin-1 and SATB2 in the progression of Parkinson's disease.

Parkinson's disease is a neurodegenerative disease that typically results in the loss of dopaminergic neurons, especially in an area of the brain known as the substantia nigra. Here, we investigated t...

Parkinson's disease - heterogeneous and complex in its clinical presentation.

Parkinson's disease is the second most common neurodegenerative disease. Lewy bodies with alpha-synuclein as the major component and loss of dopaminergic nerve cells in substantia nigra are neuropatho...

Clinical Trials [10812 Associated Clinical Trials listed on BioPortfolio]

Effect of Noninvasive Brain Stimulation on Hypokinetic Dysarthria in Parkinson's Disease

Hypokinetic dysarthria (HD) is common in Parkinson's disease (PD) patients and responds only partially to pharmacotherapy and surgery. The investigators will explore long-term effects of r...

The Effect of LSVT LOUD for Mandarin-speaking Individuals With Hypokinetic Dysarthria Due to Parkinson's Disease

A handful of studies have examined the effects of the Lee Silverman Voice Treatment (LSVT) LOUD on hypokinetic dysarthria in English speakers with Parkinson's disease (PD). Although LSVT L...

Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria

Huntington's disease is a hereditary disease of rare autosomal dominant transmission, both neurodegenerative and neuro-psychiatric. Clinically, there are motor symptoms (chorea), cognitive...

Rhythmic Entrainment in Bilingual Speakers With Dysarthria

The objectives of this study are to determine i) the effect of rhythmic entrainment of speech with hand gestures and auditory rhythmic cues on intelligibility and speech naturalness in Spa...

Prospective Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease

Pilot study: - Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) - Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on...

Medical and Biotech [MESH] Definitions

Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously.

Proteins associated with sporadic or familial cases of PARKINSON DISEASE.

A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)

A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900)

Quick Search

DeepDyve research library

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Searches Linking to this Article